Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.42 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.36 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.36 |
| ▸ | ANPEP | P15144 | 3/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.35 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4006238 | 1.00 | CACNA2D1 (0.42) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4014321 | 1.00 | CACNA2D1 (0.42) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4006956 | 0.90 | CACNA2D1 (0.53) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4014165 | 0.90 | CACNA2D1 (0.53) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4014272 | 0.90 | CACNA2D1 (0.53) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4008065 | 0.89 | GPR88 (0.44) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4007783 | 0.89 | GPR88 (0.44) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4005361 | 0.89 | GPR88 (0.44) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4014200 | 0.87 | CACNA2D1 (0.39) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4010221 | 0.87 | CACNA2D1 (0.39) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491835-B2 | Prodrugs of amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-02-17 | — | — | US | claimed |
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | VIATRIS SPECIALTY LLC. | 2005-03-31 | — | — | US | claimed |
| US-7491835-B2 | Prodrugs of amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1670750-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030703-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | VIATRIS SPECIALTY LLC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | CACNA2D1 40/4885CACNB3 77/4885CACNA1C 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.